Anti-IL17A (Cosentyx) (secukinumab biosimilar) mAb, IgG1, Human, Monoclonal

Artikelnummer: ABI-12-9156-50
Artikelname: Anti-IL17A (Cosentyx) (secukinumab biosimilar) mAb, IgG1, Human, Monoclonal
Artikelnummer: ABI-12-9156-50
Hersteller Artikelnummer: 12-9156-50
Alternativnummer: ABI-12-9156-50-50UG
Hersteller: Abeomics
Wirt: Human
Kategorie: Antikörper
Applikation: FACS
Spezies Reaktivität: Human
Alternative Synonym: CTLA-8,CTLA8,IL-17,IL-17A,IL17
Secukinumab (Cosentyx) is a biologic medication used to treat psoriatic arthritis, moderate to severe plaque psoriasis. Biologics are medicines that are human-made through genetic engineering techniques and closely related to a protein that occurs naturally in the body. Secukinumab blocks an inflammatory protein called IL-17, thus improving joint pain and swelling from arthritis and rash from psoriasis. Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Klonalität: Monoclonal
Isotyp: IgG1
Reinheit: Purified from cell culture supernatant by affinity chromatography
Target-Kategorie: IL17A
Application Verdünnung: FACS 1:100